ReviewFrontiers in cardiovascular medicine2026
Functional coronary vascular disease: endotype-based classification, diagnosis, and targeted management.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Angina and exertional dyspnea are hallmark manifestations of coronary artery disease (CAD), traditionally linked to obstructive epicardial lesions. However, a substantial subset of patients experience angina despite angiographically non-obstructive coronary arteries (<50%), termed angina with non-obstructive coronary arteries (ANOCA). ANOCA may progress to ischemia with non-obstructive coronary arteries (INOCA), myocardial infarction with non-obstructive coronary arteries (MINOCA), and ischemic cardiomyopathy. Despite advances in diagnostic modalities, the underlying pathophysiology remains underappreciated, and management often lacks precision. Pathophysiology: ANOCA and INOCA encompass heterogeneous functional and structural coronary abnormalities, including endothelial dysfunction, impaired vasodilation, and inappropriate vasoconstriction of epicardial or microvascular vessels. Epicardial arteries serve primarily as conduits, whereas the microcirculation regulates coronary flow, mediating myocardial perfusion through nitric oxide, adenosine, and prostacyclin signalling. Disruption of these mechanisms precipitates ischemia despite normal epicardial anatomy, defining distinct endotypes with diagnostic and therapeutic relevance. Diagnosis and management: Evaluation involves stepwise assessment from non-invasive testing, including ECG, laboratory studies, echocardiography, and coronary computed tomography, to invasive functional testing for endotype characterization. Management should integrate endotype-specific pharmacologic therapies such as calcium channel blockers, nitrates, ranolazine, ACE inhibitors, and beta-blockers with non-pharmacologic interventions including lifestyle modification and overall cardiovascular risk reduction. Conclusion: Personalized, endotype-guided strategies targeting both pathophysiology and modifiable risk factors are essential to optimize symptom control, prevent disease progression, and reduce major adverse cardiovascular events in patients with ANOCA and INOCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.